We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunomarker Expression Clarified for Thoracic Tumors

By LabMedica International staff writers
Posted on 03 Jan 2016
Comprehensive morphological and immunohistochemical subtyping of tumors is of growing importance for therapy selection and propelled the concept of a tumor-specific, individualized treatment. More...


Thoracic pathologists are frequently faced with tissue specimens from intrathoracic/mediastinal tumors and specifically the differentiation between thymic and pulmonary squamous cell carcinomas (SqCC) can be challenging. For non-small-cell lung cancer (NSCLC) the current classification therefore has been extended by the concept of immunophenotyping from biopsies to resection specimens.

Scientists at Heidelberg University (Germany) identified a cohort of 1,465 patients for whom formalin-fixed paraffin-embedded specimens of NSCLC were available. Prior to tissue microarray (TMA) construction, a hematoxylin and eosin (H&E)-stained slide of each block was analyzed in order to select representative tumor-containing regions.

A TMA machine (AlphaMetrix Biotech; Rödermark, Germany) was used to extract a tandem 1.0 mm cylindrical core sample from each tissue donor block. Immunohistochemistry (IHC) was performed with commercially available antibodies and TMA slides were deparaffinized and pretreated with antigen retrieval buffer. Subsequent steps were performed on a BenchMark Ultra, immunostaining instrument (Ventana, Tucson, AZ, USA). The TMA resection specimens were stained with antibodies against CD117 and CD5.

CD117 was positive in 145 out of 1,457 evaluable cases (9.9%) and CD5 was positive in 133 out of 1,427 evaluable cases (9.3%). Coexpression of CD117 and CD5 was seen in 28 cases (1.9%). Among the 145 cases that were positive for CD117, 97 (66.8%) were adenocarcinomas (ADC), 34 (23.4%) were SqCC, 5 (3.4%) were adenosquamous carcinomas (ADSqCC), 8 (5.5%) were large cell carcinomas (LC), and one (0.6%) was a pleomorphic carcinoma (PC). In the CD5 positive group consisting of 133 cases, 123 (92.4%) were ADC, four (3.0%) were ADSqCC, three (2.2%) LC and three (2.2%) were PC. None of the 586 SqCC showed expression of CD5.

The authors concluded that a substantial subset of NSCLC exhibit positivity of CD117 and CD5. Since CD5 expression was not observed in pulmonary SqCC, but is expressed in the majority of thymic squamous cell carcinomas, the application of this immunomarker is a valuable tool in the differential diagnosis of thoracic neoplasms. The study was published on December 8, 2015, in the journal Diagnostic Pathology.

Related Links:

Heidelberg University
AlphaMetrix Biotech  
Ventana  



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.